(AMBU-B) Ambu - CO
Sector: Healthcare | Industry: Medical Devices | Exchange: CO (Denmark) | Market Cap: 16.583m DKK | Total Return: -31.9% in 12m
Avg Turnover: 52.7M
EPS Trend: 80.5%
Qual. Beats: -1
Rev. Trend: 98.4%
Qual. Beats: -1
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Ambu A/S is a Denmark-based medical technology company specializing in the development and distribution of diagnostic and life-supporting equipment. Its primary portfolio includes single-use endoscopy solutions, neurology and cardiology electrodes, and airway management tools for anesthesia and emergency care.
The company operates within the specialized Health Care Equipment sub-industry, where the shift from reusable to single-use endoscopes is a key structural trend aimed at reducing cross-contamination risks and hospital reprocessing costs. Ambu utilizes a direct sales model in major markets like North America and Europe while leveraging distributors for global reach.
- Single-use endoscopy adoption accelerates across pulmonology and ENT segments
- Operating margin expansion driven by manufacturing scale and cost transformation
- FDA regulatory shift toward disposable endoscopes reduces cross-contamination risks
- Competitive pricing pressure from traditional reusable scope manufacturers intensifies
| Net Income: 477.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.49 > 1.0 |
| NWC/Revenue: 32.45% < 20% (prev 32.36%; Δ 0.09% < -1%) |
| CFO/TA 0.11 > 3% & CFO 847.0m > Net Income 477.0m |
| Net Debt (-140.0m) to EBITDA (1.04b): -0.14 < 3 |
| Current Ratio: 2.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (266.6m) vs 12m ago 0.67% < -2% |
| Gross Margin: 55.82% > 18% (prev 60.27%; Δ -4.45% > 0.5%) |
| Asset Turnover: 81.28% > 50% (prev 78.69%; Δ 2.59% > 0%) |
| Interest Coverage Ratio: 10.85 > 6 (EBIT TTM 651.0m / Interest Expense TTM 60.0m) |
| A: 0.26 (Total Current Assets 3.01b - Total Current Liabilities 1.03b) / Total Assets 7.61b |
| B: 0.77 (Retained Earnings 5.86b / Total Assets 7.61b) |
| C: 0.09 (EBIT TTM 651.0m / Avg Total Assets 7.51b) |
| D: 4.05 (Book Value of Equity 6.10b / Total Liabilities 1.50b) |
| Altman-Z'' = 9.06 = AAA |
| DSRI: 1.03 (Receivables 979.0m/911.0m, Revenue 6.10b/5.83b) |
| GMI: 1.08 (GM 60.27% / 55.82%) |
| AQI: 0.96 (AQ_t 0.45 / AQ_t-1 0.46) |
| SGI: 1.05 (Revenue 6.10b / 5.83b) |
| TATA: -0.05 (NI 477.0m - CFO 847.0m) / TA 7.61b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of June 20, 2026, the stock is trading at DKK 62.95 with a total of 2,498,540 shares traded.
Over the past week, the price has changed by -1.82%,
over one month by -3.27%,
over three months by -11.16% and
over the past year by -31.92%.
Ambu has no consensus analysts rating.
P/E Trailing = 35.1117
P/E Forward = 21.2766
P/S = 2.6864
P/B = 2.7072
P/EG = 2.8489
Revenue TTM = 6.10b DKK
EBIT TTM = 651.0m DKK
EBITDA TTM = 1.04b DKK
Long Term Debt = 17.0m DKK (from longTermDebt, last quarter)
Short Term Debt = 170.0m DKK (from shortTermDebt, last quarter)
Debt = 551.0m DKK (from shortLongTermDebtTotal, last quarter) (leases 534.0m already included)
Net Debt = -140.0m DKK (calculated: Debt 551.0m - CCE 691.0m)
Enterprise Value = 16.4b DKK (16.6b + Debt 551.0m - CCE 691.0m)
Interest Coverage Ratio = 10.85 (Ebit TTM 651.0m / Interest Expense TTM 60.0m)
EV/FCF = 26.95x (Enterprise Value 16.4b / FCF TTM 610.0m)
FCF Yield = 3.71% (FCF TTM 610.0m / Enterprise Value 16.4b)
FCF Margin = 9.99% (FCF TTM 610.0m / Revenue TTM 6.10b)
Net Margin = 7.81% (Net Income TTM 477.0m / Revenue TTM 6.10b)
Gross Margin = 55.82% ((Revenue TTM 6.10b - Cost of Revenue TTM 2.70b) / Revenue TTM)
Gross Margin QoQ = 60.27% (prev 60.78%)
Tobins Q-Ratio = 2.16 (Enterprise Value 16.4b / Total Assets 7.61b)
Interest Expense / Debt = 10.89% (Interest Expense 60.0m / Debt 551.0m)
Taxrate = 23.06% (143.0m / 620.0m)
NOPAT = 500.8m (EBIT 651.0m * (1 - 23.06%))
Current Ratio = 2.92 (Total Current Assets 3.01b / Total Current Liabilities 1.03b)
Debt / Equity = 0.09 (Debt 551.0m / totalStockholderEquity, last quarter 6.10b)
Debt / EBITDA = -0.14 (Net Debt -140.0m / EBITDA 1.04b)
Debt / FCF = -0.23 (Net Debt -140.0m / FCF TTM 610.0m)
Total Stockholder Equity = 6.02b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.35% (Net Income 477.0m / Total Assets 7.61b)
RoE = 7.92% (Net Income TTM 477.0m / Total Stockholder Equity 6.02b)
RoCE = 10.78% (EBIT 651.0m / Capital Employed (Equity 6.02b + L.T.Debt 17.0m))
RoIC = 7.78% (NOPAT 500.8m / Invested Capital 6.44b)
WACC = 7.86% (E(16.6b)/V(17.1b) * Re(7.84%) + D(551.0m)/V(17.1b) * Rd(10.89%) * (1-Tc(0.23)))
Discount Rate = 7.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 20.46 | Cagr: 0.04%
[DCF] Terminal Value 77.97% ; FCFF base≈530.0m ; Y1≈607.6m ; Y5≈894.2m
[DCF] Fair Price = 59.23 (EV 13.5b - Net Debt -140.0m = Equity 13.6b / Shares 229.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 80.47 | EPS CAGR: 68.17% | SUE: -1.36 | # QB: -1
Revenue Correlation: 98.38 | Revenue CAGR: 11.42% | SUE: -2.02 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.62 | Chg30d=-7.24% | Revisions=-33% | Analysts=2
EPS current Year (2026-09-30): EPS=2.31 | Chg30d=+0.13% | Revisions=-33% | GrowthEPS=+1.3% | GrowthRev=+6.9%
EPS next Year (2027-09-30): EPS=3.08 | Chg30d=-3.42% | Revisions=-56% | GrowthEPS=+33.4% | GrowthRev=+11.3%
[Analyst] Revisions Ratio: -56%